Saturday, 22 September 2012

Pro Pet Shampoo





Dosage Form: FOR ANIMAL USE ONLY

Pro Pet 4 in 1 Shampoos


Pro Pet 4 in 1 Shampoos are scientifically formulated with our exclusive HydrCoat Complex to provide the ultimate in pet grooming care. Clean, Deodorize, Condition and Detangle-all in one bottle! Unique cleansing and conditioning compounds work together for maximum effectiveness, leaving your pet's coat healthy and shiny.


HydraCoat Complex is an exclusive blend of hydrating cleansers, vitamins, proteins and essential botanicals to deeply penetrate and moisturize.


Formula Facts


Extra - thick antibacterial formula specially formulated to eliminate pet odors.


Botanical oil extracts


Fortified with natural oils including Aloe vera to condition skin and protect your pet's coat.


Long lasting fragrance


Green apple scent leaves coat smelling clean and fresh



Directions for Use


Wet pet completely. Avoiding the eyes, apply shampoo and work into a lather. Rinse pet thoroughly and repeat if necessary. Towel dry and comb as needed. Weekly shampooing is recommended, if product comes into contact with pet's eyes, rinse thoroughly with fresh water.



Active Ingredients


Triclosan 0.15%



Purpose


purpose: deodoizing



Inactive Ingredients


Water, sodium Laureth Sulfate, Sodium Lauryl Sulfate, Sodium Chloride, Cocamide DEA, Cocamidoproppyl Betaine, Propylene Glycol, Extract of Chamomille, Extract of Comfrey, Aloe Vera, Diazolidinyl Urea, Methylparaben, Propylparaben, Citric Acid, D C green #8, FD C Blue # 1, FD C Yellow #5.



KEEP THIS PRODUCT OUT OF REACH OF CHILDREN AND PETS TO AVOID UNINTENDED CONSUMPTION



Pro Pet


Antibacterial


Deodorizing


Shampoo


4 in 1 Formula


Cleans


Deodorizes


Conditions


Detangles


Long Lasting


Apple Scent


Contains Natural Antibacterial Agents Including Chamomile and Comfrey to Destroy Pet Odors


Net 20 Fl. Oz. (591 ml)










PRO PET 
antibacterial deodorizing shampoo  shampoo










Product Information
Product TypeOTC ANIMAL DRUGNDC Product Code (Source)24730-671
Route of AdministrationTOPICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Triclosan (Triclosan)Triclosan0.89 g  in 591 g


































Inactive Ingredients
Ingredient NameStrength
Water 
SODIUM LAURYL SULFATE 
SODIUM CHLORIDE 
SODIUM LAURETH SULFATE 
COCAMIDOPROPYL BETAINE 
PROPYLENE GLYCOL 
COMFREY 
ALOE VERA LEAF 
DIAZOLIDINYL UREA 
METHYLPARABEN 
PROPYLPARABEN 
CITRIC ACID 
D&C GREEN NO. 8 
FD&C BLUE NO. 1 
FD&C YELLOW NO. 5 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
124730-671-13591 g In 1 BOTTLE, PLASTICNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other01/01/2001


Labeler - United Pet Group (931135730)









Establishment
NameAddressID/FEIOperations
JUNGLE LABORATORIES CORPORATION032615270manufacture
Revised: 02/2010United Pet Group



Thursday, 20 September 2012

Genaton


Pronunciation: al-JIN-ik AS-id/a-LOO-min-um/mag-NEE-zee-um/SO-dee-um bye-KAR-boe-nate
Generic Name: Alginic Acid/Aluminum/Magnesium/Sodium Bicarbonate
Brand Name: Examples include Gaviscon-2 and Genaton


Genaton is used for:

Treating acid indigestion, heartburn, and sour stomach. It may also be used for other conditions as determined by your doctor.


Genaton is an antacid. It works by neutralizing acid in the stomach.


Do NOT use Genaton if:


  • you are allergic to any ingredient in Genaton

  • you have alkalosis (too little acid in the body) or low blood levels of calcium or chloride

  • you are vomiting

  • you are also taking citrate salts (found in some calcium supplements, antacids, and laxatives)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Genaton:


Some medical conditions may interact with Genaton. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have Alzheimer disease, appendicitis, diarrhea, a stomach blockage, kidney or liver problems, or an ileostomy

  • if you have congestive heart failure, decreased urination, swelling (fluid retention), or rectal bleeding of unknown cause

  • if you have recently had stomach bleeding

  • if you are on a low salt diet

Some MEDICINES MAY INTERACT with Genaton. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Cation exchange resins (eg, sodium polystyrene sulfonate) or citrate salts (found in some calcium supplements, antacids, and laxatives) because they may increase the actions and the risk of Genaton's side effects

  • Anticoagulants (eg, warfarin), quinidine, sulfonylureas (eg, glyburide), or sympathomimetics (eg, pseudoephedrine) because their actions and the risk of their side effects may be increased

  • Angiotensin-converting enzyme (ACE) inhibitors (eg, enalapril), anorexiants (eg, amphetamine), beta-blockers (eg, propranolol), bisphosphonates (eg, risedronate), cephalosporins (eg, cephalexin), corticosteroids (eg, prednisone), corticotropin, cyclosporine, delavirdine, digoxin, imidazoles (eg, ketoconazole), lithium, mycophenolate, penicillamine, quinolones (eg, ciprofloxacin), tetracyclines (eg, doxycycline), or thyroid hormones (eg, levothyroxine) because their effectiveness may be decreased by Genaton, especially when taken at the same time as Genaton

This may not be a complete list of all interactions that may occur. Ask your health care provider if Genaton may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Genaton:


Use Genaton as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Genaton by mouth with or without food.

  • Chew thoroughly before swallowing.

  • Do not use Genaton within 2 hours before or after taking a beta-blocker (eg, propranolol), bisphosphonate (eg, risedronate), cephalosporin (eg, cephalexin), corticosteroid (eg, hydrocortisone), delavirdine, digoxin, imidazole (eg, ketoconazole), penicillamine, or sulfonylurea (eg, glyburide) because their effectiveness may be decreased by Genaton.

  • If you miss a dose of Genaton and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Genaton.



Important safety information:


  • Do NOT take more than the recommended dose or take the maximum dose for longer than 2 weeks without checking with your doctor.

  • If your symptoms do not get better within 2 weeks or if they get worse, or if you experience black, tarry stools or vomit that looks like coffee grounds, check with your doctor.

  • Genaton has aluminum and magnesium in it. Before you begin taking any new prescription or over-the-counter medicine, read the ingredients to see has aluminum or magnesium in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Genaton while you are pregnant. If you are or will be breast-feeding while you use Genaton, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Genaton:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; diarrhea.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); loss of appetite; muscle weakness; nausea; slow reflexes; vomiting.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Genaton:

Store Genaton between 59 and 86 degrees F (15 and 30 degrees C). Store in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Genaton out of the reach of children and away from pets.


General information:


  • If you have any questions about Genaton, please talk with your doctor, pharmacist, or other health care provider.

  • Genaton is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Genaton. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Genaton resources


  • Genaton Use in Pregnancy & Breastfeeding
  • Genaton Drug Interactions
  • Genaton Support Group
  • 3 Reviews for Genaton - Add your own review/rating


  • Genaton Concise Consumer Information (Cerner Multum)



Compare Genaton with other medications


  • GERD
  • Indigestion

Wednesday, 19 September 2012

Nebilet 5mg Tablets





NEBILET 5 mg tablets



Nebivolol




Read all this leaflet carefully before you start using this medicine.



  • Keep this leaflet. You may need to read it again.

  • If you have any further questions, ask your doctor or pharmacist.

  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.




In this leaflet:



  • 1. What Nebilet is and what it is used for

  • 2. Before you take Nebilet

  • 3. How to take Nebilet

  • 4. Possible side effects

  • 5. How to store Nebilet

  • 6. Further information





What Nebilet Is And What It Is Used For



Nebilet contains nebivolol, a cardiovascular drug belonging to the group of selective beta-blocking agents (i.e. with a selective action on the cardiovascular system). It prevents increased heart rate, controls heart pumping strength. It also exerts a dilating action on blood vessels, which contributes as well to lower blood pressure.



It is used to treat raised blood pressure (hypertension).



Nebilet is also used to treat mild and moderate chronic heart failure in patients aged 70 or over, in addition to other therapies.





Before You Take Nebilet




Do not take Nebilet



  • if you are allergic (hypersensitive) to nebivolol or any of the other ingredients of Nebilet

  • if you have one or more of the following disorders:

    • low blood pressure

    • serious circulation problems in the arms or legs

    • very slow heartbeat (less than 60 beats per minute)

    • certain other serious heart rhythm problems (e.g. 2nd and 3rd degree atrioventricular block, heart conduction disorders).

    • heart failure, which has just occurred or which has recently become worse, or you are receiving treatment for circulatory shock due to acute heart failure by intravenous drip feed to help your heart work

    • asthma or wheezing (now or in the past)

    • untreated phaeochromocytoma, a tumour located on top of the kidneys (in the adrenal glands)

    • liver function disorder

    • a metabolic disorder (metabolic acidosis), for example, diabetic ketoacidosis.





Take special care with Nebilet



Inform your doctor if you have or develop one of the following problems:



  • abnormally slow heartbeat

  • a type of chest pain due to spontaneously occurring heart cramp called Prinzmetal angina

  • untreated chronic heart failure

  • 1st degree heart block (a kind of light heart conduction disorder that affects heart rhythm)

  • poor circulation in the arms or legs, e.g. Raynaud’s disease or syndrome, cramp-like pains when walking

  • prolonged breathing problems

  • diabetes: This medicine has no effect on blood sugar, but it could conceal the warning signs of a low sugar level (e.g. palpitations, fast heartbeat).

  • overactive thyroid gland: This medicine may mask the signs of an abnormally fast heart rate due to this condition

  • allergy: This medicine may intensify your reaction to pollen or other substances you are allergic to

  • psoriasis (a skin disease - scaly pink patches) or if you have ever had psoriasis

  • if you have to have surgery, always inform your anaesthetist that you are on Nebilet before being anaesthetised.

If you have serious kidney problems do not take Nebilet for heart failure and tell your doctor.



You will be regularly monitored at the beginning of your treatment for chronic heart failure by an experienced physician (see section 3).



This treatment should not be stopped abruptly unless clearly indicated and evaluated by your doctor (see section 3).





Children and adolescents



Because of the lack of data on the use of the product in children and adolescents, Nebilet is not recommended for use in them.





Taking other medicines



Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Certain medicines cannot be used at the same time, while other drugs require specific changes (in the dose, for example).



Always tell your doctor if you are using or receiving any of the following medicines in addition to Nebilet:



  • Medicines for controlling the blood pressure or medicines for heart problems (such as amiodarone, amlodipine, cibenzoline, clonidine, digoxin, diltiazem, disopyramide, felodipine, flecainide, guanfacin, hydroquinidine, lacidipine, lidocaine, methyldopa, mexiletine, moxonidine, nicardipine, nifedipine, nimodipine, nitrendipine, propafenone, quinidine, rilmenidine, verapamil).


  • Sedatives and therapies for psychosis (a mental illness) e.g. barbiturates (also used for epilepsy), phenothiazine (also used for vomiting and nausea) and thioridazine.


  • Medicines for depression e.g. amitriptyline, paroxetine, fluoxetine.


  • Medicines used for anaesthesia during an operation.


  • Medicines for asthma, blocked nose or certain eye disorders such as glaucoma (increased pressure in the eye) or dilation (widening) of the pupil.


  • All these drugs as well as nebivolol may influence the blood pressure and/or heart function.


  • Medicines for treating excessive stomach acid or ulcers (antacid drug), e.g. cimitedine: you should take Nebilet during a meal and the antacid drug between meals.




Taking Nebilet with food and drink



Nebilet can be taken with food or on an empty stomach, but the tablet is best taken with some water.





Pregnancy and breast-feeding



Nebilet should not be used during pregnancy, unless clearly necessary.



It is not recommended for use while breast-feeding.



Ask your doctor or pharmacist for advice before taking any medicine.





Driving or operating machinery



This medicine may cause dizziness or fatigue. If affected, do not drive or operate machinery.





Important information about some of the ingredients of Nebilet



This product contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.






How To Take Nebilet



Always take Nebilet exactly as your doctor has told you. You should check with your doctor if you are not sure.



Nebilet may be taken before, during or after the meal, but, alternatively, you can take it independently of
meals. The tablet is best taken with some water.




Treatment of raised blood pressure (hypertension)



  • The usual dose is 1 tablet per day. The dose should be taken preferably at the same time of the day.


  • Elderly patients and patients with a kidney disorder will usually start with ½ (half) tablet daily.


  • The therapeutic effect on blood pressure becomes evident after 1-2 weeks of treatment. Occasionally, the optimal effect is reached only after 4 weeks.




Treatment of chronic heart failure



  • Your treatment will be started and closely supervised by an experienced physician.

  • Your doctor will start your treatment with ¼ (quarter) tablet per day. This may be increased after 1-2 weeks to ½ (half) tablet per day, then to 1 tablet per day and then to 2 tablets per day until the correct dose is reached for you. Your doctor will prescribe the dose that is right for you at each step and you should closely follow his/her instructions.

  • The maximum recommended dose is 2 tablets (10mg) a day.

  • You will need to be under the close supervision for 2 hours by an experienced physician when you start treatment and every time your dose is increased

  • Your doctor may reduce your dose if necessary

  • You should not stop treatment abruptly as this can make your heart failure worse.

  • Patients with serious kidney problems should not take this medicine.

  • Take your medicine once daily, preferably at about the same time of day.

If you have been told by your doctor to take ¼ (quarter) or ½ (half) tablet daily, please refer to the instructions below on how to break Nebilet 5 mg cross-scored tablets.



  • Place the tablets onto a flat, hard surface (e.g. a table or worktop), with the cross score facing up.


  • Break the tablet by pushing it with the index fingers of both hands placed along one breakmark (Diagrams 1 and 2).


  • Tablet quarters are obtained by breaking the halves in the same way (Diagrams 3 and 4).

Diagrams 1 and 2: Easy breaking of the Nebivolol 5 mg cross-scored tablet in half.





Diagrams 3 and 4: Easy breaking of half of the Nebivolol 5 mg cross-scored tablet into quarters.



  • Your doctor may decide to combine Nebilet tablets with other medicines to treat your condition.

  • Do not use in children or adolescents.




If you take more Nebilet than you should



If you accidentally take an overdose of this medicine, tell your doctor of pharmacist immediately. The most frequent symptoms and signs of a Nebilet overdose are very slow heart beat (bradycardia), low
blood pressure with possible fainting (hypotension), breathlessness such as in asthma (bronchospasm),
and acute heart failure.



You can take activated charcoal (which is available at your pharmacy) while you wait for the arrival of the doctor.





If you forget to take Nebilet



If you forget a dose of Nebilet, but remember a little later on that you should have taken it, take that day’s dose as usual. However, if a long delay has occurred (e.g. several hours), so that the next due dose is
near, skip the forgotten dose and take the next, scheduled, normal dose at the usual time. Do not take a
double dose. Repeated skipping, however, should be avoided.





If you stop taking Nebilet



You should always consult with your doctor before stopping Nebilet treatment, whether you are taking it for high blood pressure or chronic heart failure.



You should not stop Nebilet treatment abruptly as this can temporarily make your heart failure worse. If it is necessary to stop Nebilet treatment for chronic heart failure, the daily dose should be decreased gradually,
by halving the dose, at weekly intervals.



If you have any further questions on the use of this product, ask your doctor or pharmacist.






Possible Side Effects



Like all medicines, Nebilet can cause side effects, although not everybody gets them.



When Nebilet is used for the treatment of raised blood pressure, the possible side effects are:




Common side effects (more than 1 person in every 100 treated but fewer than 1 person in every 10 treated):



  • headache

  • dizziness

  • tiredness

  • an unusual itching or tingling feeling

  • diarrhoea

  • constipation

  • nausea

  • shortness of breath

  • swollen hands or feet.




Uncommon side effects (more than 1 person in every 1,000 treated, but fewer than 1 person in every 100 treated):



  • slow heartbeat or other heart complaints

  • low blood pressure

  • cramp-like leg pains on walking

  • abnormal vision

  • impotence

  • feelings of depression

  • digestive difficulties (dyspepsia), gas in stomach or bowel, vomiting

  • skin rash, itchiness

  • breathlessness such as in asthma, due to sudden cramps in the muscles around the airways (bronchospasm)

  • nightmares.




Very rare side effects (fewer than 1 person in every 10,000 treated):



  • fainting

  • worsening of psoriasis (a skin disease - scaly pink patches).



The following side effects have been reported only in some isolated cases during Nebilet treatment:



  • whole-body allergic reactions, with generalised skin eruption (hypersensitivity reactions);

  • rapid-onset swelling, especially around the lips, eyes, or of the tongue with possible sudden difficulty breathing (angioedema).

In a clinical study for chronic heart failure, the following side effects were seen:




Very common side effects (more than 1 person in every 10 treated):



  • slow heart beat

  • dizziness




Common side effects (more than 1 person in every 100 but less than 1 person in every 10 treated):



  • worsening of heart failure

  • low blood pressure (such as feeling faint when getting up quickly)

  • inability to tolerate this medicine

  • a kind of light heart conduction disorder that affects heart rhythm (1st degree AV-block)

  • swelling of the lower limbs (such as swollen ankles).

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.






How To Store Nebilet



Keep out of the reach and sight of children.



This medicinal product does not require any special storage condition.



Do not take Nebilet after the expiry date (‘EXP’) which is stated on the box and on the blister pack.



Nebilet should not be disposed of via wastewater or household waste.



Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.





Further Information




What Nebilet contains



  • The active substance is Nebivolol 5 mg (as nebivolol hydrochloride): 2.5 mg of d-nebivolol and 2.5 mg of l-nebivolol.


  • The other ingredients are: lactose monohydrate, polysorbate 80 (E433), hypromellose (E464), maize starch, croscarmellose sodium (E468), microcrystalline cellulose (E460), colloidal anhydrous silica (E551), magnesium stearate (E572).




What Nebilet looks like and contents of the pack



Nebilet is available as white, round, cross-scored tablets in packs of 7, 14, 28, 30, 50, 56, 90, 100, 500 tablets. Tablets are provided in blister packs (PVC/aluminium blister).



(Not all pack sizes may be marketed)





Marketing Authorisation Holder




Menarini International Operations Luxembourg S.A.

1, Avenue de la Gare L-1611

Luxembourg





Manufacturer




Berlin-Chemie AG

Glienicker Weg 125

12489 Berlin

Germany




This medicinal product is authorised in the Member States of the EEA under the following names:



  • Austria: Nomexor

  • Belgium: Hypoloc

  • Denmark: Nebilet

  • Finland: Nebilet

  • France: Hypoloc

  • Germany: Hypoloc

  • Greece: Hypoloc

  • Ireland: Nebilet

  • Italy: Lobivon

  • Iceland: Nebilet

  • Luxembourg: Hypoloc

  • Norway: Nebilet

  • Portugal: Hypoloc

  • Spain: Silostar

  • Sweden: Nebilet

  • The Netherlands: Hypoloc

  • United Kingdom: Nebilet



This leaflet was last approved in 06/2008




Menarini International Operations Luxembourg S.A.

1, Avenue de la Gare L-1611

Luxembourg



Marketed by




A. MENARINI Pharma U.K. S.R.L.

Menarini House

Wooburn Green

Buckinghamshire

HP10 0HH




0001/08





Thursday, 13 September 2012

Hypurin Bovine Lente





1. Name Of The Medicinal Product



Hypurin® Bovine Lente 100 IU/ml injection


2. Qualitative And Quantitative Composition



Crystalline Insulin Ph Eur (Bovine) 100 IU/ml.



Insulin Zinc Suspension (Mixed) Ph Eur (Bovine)



For excipients, see 6.1



3. Pharmaceutical Form



Suspension for injection.



A white suspension



4. Clinical Particulars



4.1 Therapeutic Indications



The treatment of insulin dependent diabetes mellitus.



Hypurin® Bovine Lente may be used for diabetics requiring a depot insulin of medium to extended duration.



4.2 Posology And Method Of Administration



To be determined by the physician according to the needs of the patient.



Administered subcutaneously. It is not recommended for intramuscular use and should not be given intravenously. Onset of action occurs approximately 2 hours after subcutaneous injection with an overall duration extending up to 30 hours. Maximum effect is exerted between 8-12 hours.



Prior to use, the vial of Hypurin® Bovine Lente should be rolled gently between the palms or inverted several times.



4.3 Contraindications



Hypoglycaemia.



Hypersensitivity to insulin or to any of the excipients.



4.4 Special Warnings And Precautions For Use



In no circumstances must Hypurin® Bovine Lente be given intravenously.



Hypoglycaemia: Susceptibility to hypoglycaemia may be increased by an inaccurate or excessive dosage of insulin, the omission of a meal by the patient or increased physical activity. Correct insulin administration and awareness of the symptoms of hypoglycaemia are essential to reduce the risk of hypoglycaemia (see section 4.9).



Blood or urinary glucose concentrations should be monitored and the urine tested for ketones by patients on insulin therapy.



Newly diagnosed diabetic patients may experience fluctuating insulin requirements during the first weeks, months or even years of treatment (the so-called 'honeymoon period').



Patients transferred to Hypurin® Bovine insulins from other commercially available preparations may require dosage adjustments.



The warning symptoms of hypoglycaemia may be changed, be less pronounced or absent in certain risk groups who should be advised accordingly. These include patients:



- in whom glycaemic control is greatly improved, e.g. by intensified insulin therapy



- with a long history of diabetes



- who are elderly



- receiving concomitant treatment with certain medicinal products e.g. beta blockers or clonidine.



Elderly diabetic patients are more susceptible to episodes of severe, rapid onset hypoglycaemia.



Combination of Hypurin® insulins with pioglitazone: Cases of cardiac failure have been reported when thiazolidinediones are used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Hypurin® is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.



Insulin requirements may increase during illness (this includes infection and accidental and surgical trauma), puberty or emotional upset.



Insulin resistance is frequently associated with lipid disorders, hypertension and ischaemic heart disease. Patients with insulin resistance usually require more than 200 units of insulin daily. Insulin resistance of the type manifested by greatly increased insulin requirements may be due to factors including antibody formation although some diseases, such as infections, endocrine hyperfunctional states (e.g. acromegaly, Cushing's syndrome, thyrotoxicosis) or stress can contribute to insulin resistance.



Insulin requirements may decrease with liver disease, disease of the adrenal, pituitary or thyroid glands and coeliac disease. In patients with severe renal impairment, insulin requirements may fall and dosage reduction may be necessary. The compensatory response to hypoglycaemia may also be impaired.



Insulin requirements may be increased in the premenstrual period but may be reduced during or after a menstrual cycle.



Insulin requirements are usually reduced but occasionally increased during periods of increased activity.



Increase in subcutaneous blood flow, brought about by factors such as a hot bath, may increase the rate of absorption of insulin.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Drugs that may increase the requirement for insulin



Antipyschotics: chloropromazine



Corticosteroids



Diazoxide



Diuretics: thiazide diuretics or loop diuretics



Sympathomimetic agents



Thyroid hormone replacement therapy



Smoking may also antagonise the hypoglycaemic effect of insulin



Drugs that may decrease the requirement for insulin



ACE inhibitors



Alcohol: moderate or large amounts of alcohol (more than 2 units per day for women and more than 3 units per day for men) can decrease the requirements for insulin and may lead to hypoglycaemic attacks. Episodic heavy drinking ('binge' drinking) carries a particularly high risk of hypoglycaemic episodes.



Anabolic steroids



Analgesics: NSAIDS, or salicylates, particularly large doses of aspirin



Androgens: testosterone may enhance the hypoglycaemic effect of insulin



Anti-arrhythmics: disopyramide.



Concomitant use of insulin with quinidine may increase the risk of hypoglycaemia occurring.



Anti-depressants: monoamine oxidase inhibitors or fluoxetine.



Concomitant use of amitriptyline with insulin may lead to hypoglycaemia.



Antihypertensives: guanethidine



Antimalarials: concomitant use of insulin with antimalarials such as chloroquine or quinine may increase the risk of hypoglycaemia occurring.



Fenfluramine



Hormone antagonists: octreotide



Lipid-regulating drugs: fibrates



Mebendazole



Pentoxifylline: the hypoglycaemic activity of insulin may be potentiated by concomitant administration of high-dose pentoxifylline injection.



Tetracyclines: tetracyclines such as oxytetracycline



Drugs that may increase or decrease the requirements for insulin



Antihypertensives: clonidine. Signs and symptoms of hypoglycaemia may be masked by clonidine.



Beta blockers: beta blockers. Some of the warning signs of insulin-induced hypoglycaemia may be masked.



Calcium channel blockers: nifedipine may occasionally impair glucose tolerance.



Cyclophosphamide



Isoniazid



Lipid-regulating drugs: gemfibrozil



Oral contraceptives



4.6 Pregnancy And Lactation



Pregnancy



A decreased requirement for insulin may be observed in the early stages of pregnancy. However, in the second and third trimesters, insulin requirements may increase. Insulin requirements should therefore be assessed frequently by an experienced diabetic physician.



Maternal insulin requirements may decrease after delivery. As this decrease can be at an unpredictable rate, the maternal blood glucose should be closely monitored.



Congenital abnormality is more common in offspring of diabetic than non-diabetic women.



Lactation



Caution should be exercised when prescribing to lactating women. Lactating women may require adjustments in insulin dose and diet.



4.7 Effects On Ability To Drive And Use Machines



The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).



Patients should be advised to take precautions to avoid hypoglycaemia whilst driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.



4.8 Undesirable Effects



Metabolic disorders:



• Hypoglycaemia is the most common adverse effect associated with insulin therapy. For symptoms of hypoglycaemia, refer to section 4.9, Overdosage.



• Hypokalaemia may occur with insulin therapy.



• Insulin therapy may lead to weight gain.



General disorders and administration site conditions:



Lipodystrophy (atrophy or hypertrophy of the fat tissue) may occur at the injection site. Stinging or sensations of warmth or burning at the site of injection may also occur.



Immune system disorders:



Insulin hypersensitivity can occur with animal insulins, but appears less likely with purified insulins and there is minimal evidence that such effects occur with Hypurin insulins. Allergic reactions to phenol and m-cresol contained as preservative and to zinc and protamine may occur.



• Local hypersensitivity: Local allergic reactions to insulin such as pruritus, erythema and oedema may occur at the injection site.



• Generalised hypersensitivity: Generalised hypersensitivity may produce urticaria, nausea, dyspnoea or wheezing and, in rare cases, anaphylactic reactions. Severe, angioedema is a rare adverse effect of insulin treatment occurring most often at the initiation of therapy.



4.9 Overdose



a) Symptoms



Overdosage causes hypoglycaemia. Symptoms include yawning, hunger, pallor, restlessness, weakness, sweating, trembling, confusion, anxiety, nervousness, excitement, irritability, aggression, altered behaviour, deep respiration, cramps, headache, paraesthesia and/or numbness of the nose, mouth, fingers or toes, reduced consciousness, visual disturbance, including blurred vision and double vision, slurred speech, difficulty in finding words, difficulty in concentration, drowsiness, fatigue, convulsions, hemiplegia, paralysis, tachycardia and/or palpitations, myocardial ischaemia and cerebral oedema which, if untreated, will lead to collapse, coma and/or irreversible brain damage.



Hypokalaemia may also occur with insulin overdose.



b) Treatment



Mild hypoglycaemia will respond to oral administration of glucose or sugar and rest.



Moderately severe hypoglycaemia can be treated by intramuscular or subcutaneous injection of glucagon followed by oral carbohydrate when the patient is sufficiently recovered.



For patients who are comatose or who have failed to respond to glucagon injection an intravenous injection of strong Dextrose Injection BP should be given.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



ATC Code – A10A A



Insulin output from the pancreas of a healthy person is about 50 units per day, which is sufficient to maintain the fasting blood sugar concentration in the range 0.8 ± 0.2mg/ml. In diabetes mellitus, the blood sugar rises in an uncontrolled manner. Parenterally administered insulin causes a fall in blood sugar concentration and increased storage of glycogen in the liver. In the diabetic it raises the respiratory quotient after a carbohydrate meal and prevents the formation of ketone bodies. The rise in blood sugar concentration caused by adrenaline and corticosteroids, glucagon and posterior pituitary extract is reversed by insulin.



5.2 Pharmacokinetic Properties



Insulin is rapidly absorbed from subcutaneous tissue following injection.



Insulin is metabolised mainly in the liver and a small amount is excreted in the urine.



The plasma half-life is 4 to 5 minutes. The half-life after subcutaneous injection is about 4 hours.



5.3 Preclinical Safety Data



There are no preclinical data of relevance to the prescriber which are additional to those already included in other sections.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sodium chloride



Sodium acetate



Methylparahydroxybenzoate



Zinc oxide



Water for injections



Hydrochloric acid



Sodium hydroxide



6.2 Incompatibilities



Not applicable



6.3 Shelf Life



Three years.



Following injection of the first dose the product should be used within 28 days. Discard any unused material after this time.



6.4 Special Precautions For Storage



Store at 2oC - 8oC.



Do not freeze.



Chemical and physical in-use stability has been demonstrated for 28 days at 25°C.



From a microbiological point of view the opening carries a risk of microbial contamination and aseptic handling is a necessity.



In use storage times and conditions are the responsibility of the user.



6.5 Nature And Contents Of Container



10ml Type I glass vial sealed with a rubber bung and metal closure.



6.6 Special Precautions For Disposal And Other Handling



The vial must not be used if the contents have been frozen or it contains lumps that do not disperse on mixing.



Prior to use the vial of Hypurin® Bovine Lente should be rolled gently between the palms or inverted several times.



Hypurin® Bovine Lente may be mixed with bovine neutral insulin in the syringe, in which case the bovine neutral insulin should be the first dose to be withdrawn. The injection should then be made immediately upon withdrawal of the contents.



The use of each vial should be restricted to a single patient.



7. Marketing Authorisation Holder



Wockhardt UK Ltd



Ash Road North



Wrexham



LL13 9UF



U.K.



8. Marketing Authorisation Number(S)



PL 29831/0129



9. Date Of First Authorisation/Renewal Of The Authorisation



7th April 2008



10. Date Of Revision Of The Text



23 June 2011




Copegus


Generic Name: ribavirin (Oral route)

rye-ba-VYE-rin

Oral route(Tablet;Capsule;Solution)

Ribavirin is not effective for monotherapy treatment of chronic hepatitis C virus infection. The primary toxicity is hemolytic anemia which may result in worsening of cardiac disease and fatal and nonfatal myocardial infarctions. Avoid use in patients with significant or unstable cardiac disease. Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. Ribavirin is contraindicated in women who are pregnant and in male partners of women who are pregnant. Use 2 reliable forms of contraception and avoid pregnancy during therapy and for 6 months after completion of treatment in both female patients and in female partners of male patients who are taking ribavirin .



Commonly used brand name(s)

In the U.S.


  • Copegus

  • Rebetol

  • RibaPak

  • Ribasphere

  • Ribasphere Ribapak

  • RibaTab

Available Dosage Forms:


  • Tablet

  • Solution

  • Capsule

Therapeutic Class: Antiviral


Pharmacologic Class: Viral RNA Polymerase Inhibitor


Chemical Class: Guanosine Nucleoside Analog


Uses For Copegus


Ribavirin is used in combination with injectable interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b to treat chronic hepatitis C infection. The combination of ribavirin and peginterferon alfa-2b is used to treat adults and children 3 years of age and older who show symptoms of liver damage. Ribavirin is an antiviral agent that treats hepatitis C virus.


This medicine is available only with your doctor's prescription.


Before Using Copegus


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of ribavirin tablets in children younger than 5 years of age, ribavirin capsules and oral liquid in children younger than 3 years of age. The safety and efficacy of ribavirin tablets, capsules, and oral liquid have not been established in these age groups.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of ribavirin in the elderly. However, elderly patients are more likely to have age-related liver, kidney, or heart problems, which may require an adjustment in the dose for patients receiving ribavirin.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersXStudies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities. This drug should not be used in women who are or may become pregnant because the risk clearly outweighs any possible benefit.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Didanosine

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Abacavir

  • Azathioprine

  • Lamivudine

  • Stavudine

  • Zalcitabine

  • Zidovudine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Interferon Alfa-2b

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Autoimmune hepatitis (liver inflammation) or

  • Heart disease (unstable), or history of or

  • Liver disease (including cirrhosis), severe or

  • Sickle cell anemia (red blood cell disorder) or

  • Thalassemia major (genetic blood disorder)—Should not be used in patients with these conditions.

  • Blood or bone marrow problems (e.g., anemia, pancytopenia) or

  • Breathing problems and lung disease (e.g., pneumonia, pulmonary infiltrates, pulmonary hypertension) or

  • Colitis (inflammation of the colon) or

  • Depression or

  • Diabetes or

  • Drug abuse, history of or

  • Eye or vision problems (e.g., loss of vision, retinopathy) or

  • Heart attack, history of or

  • Heart or blood vessel disease, history of or

  • Hypertension (high blood pressure) or

  • Pancreatitis (inflammation of the pancreas) or

  • Sarcoidosis (lung disease) or

  • Thyroid disease or

  • Weakened immune system—Use with caution. May make these conditions worse.

  • Blood problems (e.g., spherocytosis) or

  • Stomach problems (e.g., bleeding), history of—Use with caution. May increase risk for severe anemia.

  • Infection (e.g., adenovirus, RSV) or

  • Influenza or parainfluenza—Copegus® should not be used in patients with these conditions. Your doctor may give you inhaled ribavirin.

  • Kidney disease—Higher blood levels of ribavirin can occur, which increases the risk of serious side effects.

  • Liver disease, decompensated or

  • Organ transplant (e.g., liver, kidney)—Use of ribavirin and peginterferon alfa-2a combination have not been established in patients with these conditions.

Proper Use of ribavirin

This section provides information on the proper use of a number of products that contain ribavirin. It may not be specific to Copegus. Please read with care.


To help clear up your infection completely, ribavirin must be given for the full time of treatment, even if you or your child begins to feel better after a few days. Also, it is important to keep the amount of medicine in your body at a steady level. To help keep the amount constant, ribavirin must be given on a regular schedule.


You should take this medicine with food.


Swallow the capsule whole. Do not crush, break, or open it.


Measure the oral liquid with a marked measuring cup or spoon. Wash the cup or spoon after each use.


This medicine should come with a Medication Guide. Read and follow the information carefully. Ask your doctor if you have any questions. Ask your pharmacist for the Medication Guide if you do not have one.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For hepatitis C virus infection, in combination with interferon alfa-2b:
    • For oral dosage form (capsules):
      • Adults—Dose is based on body weight and must be determined by your doctor. The dose is usually 1000 to 1200 milligrams (mg) per day, given as two or three capsules in the morning and three capsules at night.

      • Children 3 years of age and older—Dose is based on body weight and must be determined by your doctor. The dose is usually 15 milligrams (mg) per kilogram (kg) of body weight per day, given in 2 divided doses and taken in the morning and evening.

      • Children younger than 3 years of age—Use and dose must be determined by your doctor.


    • For oral dosage form (solution):
      • Adults—Dose is based on body weight and must be determined by your doctor. The oral solution form of this medicine is not usually prescribed for adults and teenagers.

      • Children 3 years of age and older—Dose is based on body weight and must be determined by your doctor. The dose is usually 15 milligrams (mg) per kilogram (kg) of body weight per day, given in 2 divided doses and taken in the morning and evening.

      • Children younger than 3 years of age—Use and dose must be determined by your doctor.



  • For hepatitis C virus infection, in combination with peginterferon alfa-2b:
    • For oral dosage form (capsules):
      • Adults—Dose is based on body weight and must be determined by your doctor. The dose is usually 800 to 1400 milligrams (mg) per day, given as two to three capsules in the morning and two to four capsules at night.

      • Children 3 years of age and older—Dose is based on body weight and must be determined by your doctor. The dose is usually 15 milligrams (mg) per kilogram (kg) of body weight per day, given in 2 divided doses and taken in the morning and evening.

      • Children younger than 3 years of age—Use and dose must be determined by your doctor.


    • For oral dosage form (solution):
      • Adults—Dose is based on body weight and must be determined by your doctor. The oral solution form of this medicine is not usually prescribed for adults and teenagers.

      • Children 3 years of age and older—Dose is based on body weight and must be determined by your doctor. The dose is usually 15 milligrams (mg) per kilogram (kg) of body weight per day, given in two divided doses and taken in the morning and evening.

      • Children younger than 3 years of age—Use and dose must be determined by your doctor.



  • For hepatitis C virus infection, in combination with peginterferon alfa-2a:
    • For oral dosage form (tablets):
      • Adults—Dose is based on body weight and must be determined by your doctor. The dose is usually 800 to 1200 milligrams (mg) per day, given in 2 divided doses and taken in the morning and evening.

      • Children 5 years of age and older—Dose is based on body weight and must be determined by your doctor. The dose is usually 400 to 1200 mg per day, given in 2 divided doses and taken in the morning and evening.

      • Children younger than 5 years of age—Use and dose must be determined by your doctor.



  • For hepatitis C with HIV virus coinfection, in combination with peginterferon alfa-2a:
    • For oral dosage form (tablets):
      • Adults—800 milligrams (mg) per day.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Store the capsules and tablets in a closed container at room temperature, away from heat, moisture, and direct light.


Store the oral liquid in the refrigerator or at room temperature, away from heat and direct light. Do not freeze.


Precautions While Using Copegus


It is very important that your doctor check the progress of you or your child at regular visits to make sure this medicine is working properly. Blood tests may be needed to check for unwanted effects.


Using this medicine while you are pregnant can harm your unborn baby. The medicine may also cause birth defects if the father is using it when his sexual partner becomes pregnant. If a pregnancy occurs while you are using this medicine, tell your doctor right away.


It is important to tell your doctor if you or your female sexual partner become pregnant. Your doctor may want you to join a pregnancy registry for patients taking this medicine.


A negative pregnancy test is needed in women who are of childbearing age before starting treatment with this medicine. Two forms of birth control must be used together during treatment and for 6 months after treatment ends. You will need to have pregnancy tests done regularly to make sure you are not pregnant while being treated with this medicine and after your treatment ends.


Do not use Copegus® in combination with didanosine (Videx®, Videx® EC). Using these medicines together may cause serious medical problems.


Ribavirin may cause some people to be agitated, irritable, or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed. If you, your child, or your caregiver notice any of these side effects, tell your doctor or your child's doctor right away.


Check with your doctor right away if you or your child have back, leg, or stomach pains; bleeding gums; chills; dark urine; difficulty breathing; fever; general body swelling; headache; loss of appetite; nausea or vomiting; nosebleeds; pale skin; sore throat; unusual tiredness or weakness; or yellowing of the eyes or skin. These could be symptoms of a blood disorder called anemia.


This medicine may cause serious types of allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Stop taking this medicine and call your doctor right away if you or your child have itching, hives, hoarseness, trouble with breathing, trouble with swallowing, or any swelling of the hands, face, or mouth while you are using this medicine.


Serious skin reactions can occur with this medicine. Check with your doctor right away if you or your child have blistering, peeling, or loosening of the skin; fever or chills; hives or welts; red skin lesions; a severe skin rash or acne; or sores or ulcers on the skin while you are using this medicine.


Pancreatitis may occur while you are using this medicine. Stop using this medicine and check with your doctor right away if you or your child have sudden and severe stomach pain, chills, constipation, nausea, vomiting, fever, or lightheadedness.


You or your teenager should not drink alcoholic beverages (including beer, wine, or liquor) while you are taking this medicine.


This medicine may cause some people to become dizzy, drowsy, or less alert than they are normally. Make sure you know how you react to this medicine before you or your teenager drive, operate machinery, or do anything else that could be dangerous if you are not alert.


Check with your doctor if blurred vision, decreased vision, or any other change in vision occurs while you or your child are using this medicine. Your doctor may want you to have your eyes checked by an ophthalmologist (eye doctor).


Peginterferon injection combined with ribavirin can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets in the blood, which are necessary for proper blood clotting. If this occurs, there are certain precautions you or your child can take, especially when your blood count is low, to reduce the risk of infection or bleeding:


  • If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.

  • Check with your doctor immediately if you notice any unusual bleeding or bruising; black, tarry stools; blood in the urine or stools; or pinpoint red spots on your skin.

  • Be careful when using a regular toothbrush, dental floss, or toothpick. Your medical doctor, dentist, or nurse may recommend other ways to clean your teeth and gums. Check with your medical doctor before having any dental work done.

  • Do not touch your eyes or the inside of your nose unless you have just washed your hands and have not touched anything else in the meantime.

  • Be careful not to cut yourself when you are using sharp objects such as a safety razor or fingernail or toenail cutters.

  • Avoid contact sports or other situations where bruising or injury could occur.

This medicine may cause teeth and gum problems. This medicine may cause dryness of the mouth, and a dry mouth may damage your teeth and gums if you take the medicine for a long time. To help prevent this condition, carefully brush your teeth at least two times a day and have regular visits with your dentist. For temporary relief of mouth dryness, use sugarless candy or gum, melt bits of ice in your mouth, or use a saliva substitute.


Some patients who have used this medicine have had vomiting. If you vomit during your treatment, rinse your mouth out with water. This may also help prevent damage to your teeth and gums.


Ribavirin used together with injectable peginterferon alfa-2a or peginterferon alfa-2b may affect your child's growth. Your doctor may need to check your child's height and weight during and after treatment with these medicines.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.


Copegus Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


More common
  • Anxiety

  • black, tarry stools

  • body aches or pain

  • chest pain

  • congestion

  • cough or hoarseness

  • crying

  • depersonalization

  • diarrhea

  • difficult or labored breathing

  • discouragement

  • dry mouth

  • dryness of the throat

  • dysphoria

  • euphoria

  • feeling sad or empty

  • feeling unusually cold

  • fever or chills

  • general feeling of discomfort or illness

  • headache

  • hyperventilation

  • irregular heartbeats

  • irritability

  • joint pain

  • lack of appetite

  • loss of interest or pleasure

  • lower back or side pain

  • mental depression

  • muscle aches and pains

  • nausea

  • nervousness

  • painful or difficult urination

  • pale skin

  • paranoia

  • poor concentration

  • quick to react or overreact emotionally

  • rapidly changing moods

  • restlessness

  • right upper abdominal or stomach pain

  • runny nose

  • shaking

  • shivering

  • shortness of breath

  • sleeplessness

  • sore throat

  • sores, ulcers, or white spots on the lips or in the mouth

  • sweating

  • tender, swollen glands in the neck

  • tightness in the chest

  • trouble with concentrating

  • trouble with sleeping

  • trouble with swallowing

  • troubled breathing with exertion

  • unable to sleep

  • unusual bleeding or bruising

  • unusual tiredness or weakness

  • voice changes

  • vomiting

  • wheezing

Less common
  • Bleeding gums

  • blood in the urine or stools

  • constipation

  • depressed mood

  • dry skin and hair

  • feeling cold

  • hair loss

  • husky voice

  • muscle cramps and stiffness

  • pinpoint red spots on the skin

  • right upper abdominal or stomach fullness

  • slowed heartbeat

  • weight gain

Incidence not known
  • Blistering, flaking, or peeling of the skin

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Acid or sour stomach

  • being forgetful

  • belching

  • blurred vision

  • bone pain

  • change in taste or bad, unusual, or unpleasant (after) taste

  • cracked, scaly skin

  • crusting, irritation, itching, or reddening of the skin

  • difficulty with moving

  • dizziness or lightheadedness

  • feeling of constant movement of self or surroundings

  • hair loss or thinning of the hair

  • heartburn

  • indigestion

  • lack or loss of strength

  • menstrual changes

  • pain or tenderness around the eyes and cheekbones

  • rash

  • sensation of spinning

  • sneezing

  • stomach discomfort, upset, or pain

  • stuffy nose

  • swelling

  • swollen joints

  • weight loss

Less common
  • Back pain

  • burning, dry, or itching eyes

  • discharge, excessive tearing

  • feeling of warmth

  • redness of the face, neck, arms, and occasionally, upper chest

  • redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid

  • skin rash, encrusted, scaly, and oozing

Incidence not known
  • Change in hearing

  • loss of hearing

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Copegus side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Copegus resources


  • Copegus Side Effects (in more detail)
  • Copegus Use in Pregnancy & Breastfeeding
  • Drug Images
  • Copegus Drug Interactions
  • Copegus Support Group
  • 1 Review for Copegus - Add your own review/rating


  • Copegus Prescribing Information (FDA)

  • Copegus MedFacts Consumer Leaflet (Wolters Kluwer)

  • Ribavirin Prescribing Information (FDA)

  • Ribavirin Professional Patient Advice (Wolters Kluwer)

  • Ribavirin Monograph (AHFS DI)

  • Rebetol Consumer Overview

  • Rebetol MedFacts Consumer Leaflet (Wolters Kluwer)

  • Rebetol Prescribing Information (FDA)

  • Ribasphere Consumer Overview

  • Ribasphere Prescribing Information (FDA)

  • Virazole Prescribing Information (FDA)

  • Virazole Solution MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Copegus with other medications


  • Hepatitis C

Tuesday, 11 September 2012

Nalfon


Pronunciation: FEN-oh-PROE-fen
Generic Name: Fenoprofen
Brand Name: Nalfon

Nalfon is a nonsteroidal anti-inflammatory drug (NSAID). It may cause an increased risk of serious and sometimes fatal heart and blood vessel problems (eg, heart attack, stroke). The risk may be greater if you already have heart problems or if you take Nalfon for a long time. Do not use Nalfon right before or after bypass heart surgery.


Nalfon may cause an increased risk of serious and sometimes fatal stomach ulcers and bleeding. Elderly patients may be at greater risk. This may occur without warning signs.





Nalfon is used for:

Treating rheumatoid arthritis, osteoarthritis, or mild to moderate pain. It may also be used for other conditions as determined by your doctor.


Nalfon is an NSAID. Exactly how it works is not known. It may block certain substances in the body that are linked to inflammation. NSAIDs treat the symptoms of pain and inflammation. They do not treat the disease that causes those symptoms.


Do NOT use Nalfon if:


  • you are allergic to any ingredient in Nalfon

  • you have had a severe allergic reaction (eg, severe rash, hives, trouble breathing, growths in the nose, dizziness) to aspirin or an NSAID (eg, ibuprofen, celecoxib)

  • you have recently had or will be having bypass heart surgery

  • you have severe kidney problems

  • you are in the last 3 months of pregnancy

Contact your doctor or health care provider right away if any of these apply to you.



Before using Nalfon:


Some medical conditions may interact with Nalfon. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal product, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of kidney or liver disease, diabetes, or stomach or bowel problems (eg, bleeding, perforation, ulcers)

  • if you have a history of swelling or fluid buildup, asthma, growths in the nose (nasal polyps), or mouth inflammation

  • if you have high blood pressure, blood disorders, bleeding or clotting problems, heart problems (eg, heart failure), or blood vessel disease, or if you are at risk for any of these diseases

  • if you have hearing problems, poor health, dehydration or low fluid volume, or low blood sodium levels, you drink alcohol, or you have a history of alcohol abuse

Some MEDICINES MAY INTERACT with Nalfon. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Anticoagulants (eg, warfarin), aspirin, corticosteroids (eg, prednisone), heparin, or selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine) because risk of stomach bleeding may be increased

  • Probenecid because it may increase the risk of Nalfon's side effects

  • Phenobarbital because it may decrease Nalfon's effectiveness

  • Cyclosporine, hydantoins (eg, phenytoin), lithium, methotrexate, quinolones (eg, ciprofloxacin), sulfonamides (eg, sulfamethoxazole), or sulfonylureas (eg, glipizide) because the risk of their side effects may be increased by Nalfon

  • Angiotensin-converting enzyme (ACE) inhibitors (eg, enalapril) or diuretics (eg, furosemide, hydrochlorothiazide) because their effectiveness may be decreased by Nalfon

This may not be a complete list of all interactions that may occur. Ask your health care provider if Nalfon may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Nalfon:


Use Nalfon as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Nalfon comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Nalfon refilled.

  • Take Nalfon by mouth. It may be taken with food if it upsets your stomach. Taking it with food may not lower the risk of stomach or bowel problems (eg, bleeding, ulcers). Talk with your doctor or pharmacist if you have persistent stomach upset.

  • Take Nalfon with a full glass of water (8 oz/240 mL) as directed by your doctor.

  • If you miss a dose of Nalfon and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about the proper use of Nalfon.



Important safety information:


  • Nalfon may cause dizziness or drowsiness. These effects may be worse if you take it with alcohol or certain medicines. Use Nalfon with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Serious stomach ulcers or bleeding can occur with the use of Nalfon. Taking it in high doses, for a long time, smoking, or drinking alcohol increases the risk of these side effects. Taking Nalfon with food will NOT reduce the risk of these effects. If you have severe stomach or back pain; black, tarry stools; vomit that looks like blood or coffee grounds; or unusual weight gain or swelling, contact your doctor or emergency room right away.

  • Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.

  • Nalfon is an NSAID. Before you start any new medicine, check the label to see if it has an NSAID (eg, ibuprofen) in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Do not take aspirin while you are using Nalfon unless your doctor tells you to.

  • Nalfon may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Nalfon.

  • Lab tests, including kidney function, complete blood cell counts, and blood pressure, may be performed while you use Nalfon. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Nalfon with caution in the ELDERLY; they may be more sensitive to its effects, especially stomach bleeding and kidney problems.

  • Nalfon should be used with extreme caution in CHILDREN younger than 18 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Nalfon may cause harm to the fetus. Do not use it during the last 3 months of pregnancy. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Nalfon while you are pregnant. It is not known if Nalfon is found in breast milk. Do not breast-feed while taking Nalfon.


Possible side effects of Nalfon:


All medicines can cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; diarrhea; dizziness; drowsiness; gas; headache; heartburn; nausea; stomach upset.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; trouble breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody or black, tarry stools; change in the amount of urine produced; chest pain; confusion; dark urine; decreased hearing; depression; fainting; fast or irregular heartbeat; fever, chills, or persistent sore throat; mental or mood changes; numbness of an arm or leg; one-sided weakness; red, swollen, blistered, or peeling skin; ringing in the ears; seizures; severe headache or dizziness; severe or persistent stomach pain or nausea; severe vomiting; shortness of breath; sudden or unexplained weight gain; swelling of hands, legs, or feet; unusual bruising or bleeding; unusual joint or muscle pain; unusual tiredness or weakness; vision or speech changes; vomit that looks like coffee grounds; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Nalfon side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include decreased urination; fast heartbeat; fever; loss of consciousness; seizures; severe dizziness or drowsiness; severe nausea or stomach pain; slow or troubled breathing; tremor; unusual bleeding or bruising; vomit that looks like coffee grounds.


Proper storage of Nalfon:

Store Nalfon at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Nalfon out of the reach of children and away from pets.


General information:


  • If you have any questions about Nalfon, please talk with your doctor, pharmacist, or other health care provider.

  • Nalfon is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Nalfon. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Nalfon resources


  • Nalfon Side Effects (in more detail)
  • Nalfon Dosage
  • Nalfon Use in Pregnancy & Breastfeeding
  • Drug Images
  • Nalfon Drug Interactions
  • Nalfon Support Group
  • 1 Review for Nalfon - Add your own review/rating


  • Nalfon Prescribing Information (FDA)

  • Nalfon Advanced Consumer (Micromedex) - Includes Dosage Information

  • Nalfon Concise Consumer Information (Cerner Multum)

  • Nalfon Monograph (AHFS DI)

  • Fenoprofen Prescribing Information (FDA)



Compare Nalfon with other medications


  • Gout, Acute
  • Osteoarthritis
  • Pain
  • Rheumatoid Arthritis

Sunday, 9 September 2012

Haloperidol Tablets 0.5mg B.P.





1. Name Of The Medicinal Product



Haloperidol Tablets B.P. 0.5mg.


2. Qualitative And Quantitative Composition



Each tablet contains Haloperidol B.P. 0 5mg.



3. Pharmaceutical Form



White uncoated tablets intended for oral administration to human beings.



4. Clinical Particulars



4.1 Therapeutic Indications



Psychotic conditions: Schizophrenia, paranoid psychoses, mania and hypomania.



Behavioural or mental disorders, including those associated with mental retardation, such as aggression, hyperactivity and self-mutilation.



Moderate to severe psychomotor agitation, excitement, violent or dangerous impulsive behaviour.



Gilles de la Tourette's syndrome and severe motor tics.



Restlessness and agitation in elderly patients.



Childhood behaviour disorders, especially with associated hyperactivity and aggression. As an adjunct to the short-term management of anxiety.



4.2 Posology And Method Of Administration



Route of administration: oral.



There is considerable inter-patient variation in the dosage requirements and the dosage should be individualised to meet the needs and response of each patient. In determining the initial dose, consideration should be given to the patient's age, severity of symptoms and any previous response to other anti-psychotic therapy. The dosage may be administered in single or divided doses; administration twice daily is usually sufficient.



Adults:



Psychotic conditions, behavioural or mental disorders, moderate to severe psychomotor agitation or impulsive behaviour.



The usual initial dosage ranges from 1.5 to 20mg daily, depending on the individual patient's characteristics and the severity of symptoms. It may be necessary to increase the dosage, gradually, to obtain adequate control of symptoms. The maximum daily dose should not exceed 30mg.



The usual maintenance dosage ranges from 3 to 10mg daily, and this may be achieved by gradually reducing the dosage to the lowest effective maintenance level.



Gilles de la Tourette's syndrome.



The initial dosage is usually 2mg daily. This may be increased, gradually, during the acute phase of treatment and in order to obtain maximum control of symptoms a dosage of 6 to 30mg daily may be required.



When a satisfactory response has been achieved, the dosage should be gradually reduced to the lowest effective maintenance level, which is 4mg daily for most patients.



Elderly:



Half the recommended adult starting dose may be sufficient for therapeutic response. As elderly or debilitated patients may be much more sensitive to haloperidol, the maximum and maintenance doses will generally be lower.



Anxiety.



0.5mg twice daily.



Childhood behavioural disorders and schizophrenia



Total daily maintenance dose of 0.025-0.05 mg (25 to 50 micrograms)/kg body weight per day, up to a maximum of 10 mg daily. Half the dose should be given in the morning and the other half in the evening.



Gilles de la Tourette syndrome



Oral maintenance doses of up to 10 mg/day in most patients.



Adjunct to the short-term management of anxiety



Not recommended



4.3 Contraindications



Comatose states, CNS depression, Parkinson's Disease; hypersensitivity to haloperidol; lesions of basal ganglia



In common with other neuroleptics, haloperidol has the potential to cause rare prolongation of the QT interval. Use of haloperidol is therefore contra-indicated in patients with clinically significant cardiac disorders (e.g. recent acute myocardial infarction, uncompensated heart failure, arrhythmias treated with class IA and III anti-arrhythmic medicinal products), QTc interval prolongation, history of ventricular arrhythmia or Torsades de pointes, clinically significant bradycardia, second or third degree heart block and uncorrected hypokalaemia.



Haloperidol should not be used concomitantly with other QT prolonging drugs (see section 4.5, Interaction with other medicinal products and other forms of interaction).



4.4 Special Warnings And Precautions For Use



Cases of sudden death have been reported in psychiatric patients receiving antipsychotic drugs, including haloperidol.



Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.



Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10 week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.



Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.



Increased Mortality in Elderly people with Dementia:



Data from two large observational studies showed that elderly people with dementia who are treated with antipsychotics are at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known.



Haloperidol is not licensed for the treatment of dementia-related behavioural disturbances.



Cardiovascular effects



Very rare reports of QT prolongation and/or ventricular arrhythmias, in addition to rare reports of sudden death, have been reported with haloperidol. They may occur more frequently with high doses and in predisposed patients.



The risk-benefit of haloperidol treatment should be fully assessed before treatment is commenced and patients with risk factors for ventricular arrhythmias such as cardiac disease; family history of sudden death and/or QT prolongation; uncorrected electrolyte disturbances; subarachnoid haemorrhage; starvation; or alcohol abuse should be monitored carefully (ECGs and potassium levels), particularly during the initial phase of treatment, to obtain steady plasma levels.



The risk of QT prolongation and/or ventricular arrhythmias may be increased with higher doses (see Sections 4.8 and 4.9) or with parenteral use, particularly intravenous administration. Continuous ECG monitoring should be performed for QT interval prolongation and for serious cardiac dysrhythmias if Haloperidol is administered intravenously.



Haloperidol should be used with caution in patients known to be slow metabolisers of CYP2D6, and during use of cytochrome P450 inhibitors. Concomitant use of antipsychotics should be avoided. (See Section 4.5).



Baseline ECG is recommended prior to treatment in all patients, especially in the elderly and patients with a positive personal or family history of cardiac disease or abnormal findings on cardiac clinical examination. During therapy, the need for ECG monitoring (e.g. at dose escalation) should be assessed on an individual basis. Whilst on therapy, the dose should be reduced if QT is prolonged, and haloperidol should be discontinued if the QTc exceeds 500 ms.



Periodic electrolyte monitoring is recommended, especially for patients taking diuretics, or during intercurrent illness.



An approximately 3-fold increase risk of cerebrovascular adverse events have been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. Haloperidol should be used with caution in patients with risk factors for stroke.



Neuroleptic malignant syndrome



In common with other antipsychotic drugs, Haloperidol has been associated with neuroleptic malignant syndrome: a rare idiosyncratic response characterised by hyperthermia, generalised muscle rigidity, autonomic instability, altered consciousness. Hyperthermia is often an early sign of this syndrome. Antipsychotic treatment should be withdrawn immediately and appropriate supportive therapy and careful monitoring instituted.



Tardive dyskinesia



As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy or after drug discontinuation. The syndrome is mainly characterised by rhythmic involuntary movements of the tongue, face, mouth or jaw. The manifestations may be permanent in some patients. The syndrome may be masked when treatment is reinstituted, when the dosage is increased or when a switch is made to a different antipsychotic drug. Treatment should be discontinued as soon as possible.



Extrapyramidal symptoms



In common with all neuroleptics, extrapyramidal symptoms may occur, e.g. tremor, rigidity, hypersalivation, bradykinesia, akathisia, acute dystonia.



Anti-parkinson drugs of the anticholinergic type may be prescribed as required, but should not be prescribed routinely as a preventive measure. If concomitant anti-parkinson medication is required, it may have to be continued after stopping Haloperidol if its excretion is faster than that of Haloperidol in order to avoid the development or aggravation of extrapyramidal symptoms. The physician should keep in mind the possible increase in intraocular pressure when anticholinergic drugs, including anti-parkinson agents, are administered concomitantly with Haloperidol.



Seizures/Convulsions



It has been reported that seizures can be triggered by Haloperidol. Caution is advised in patients suffering from epilepsy and in conditions predisposing to convulsions (e.g., alcohol withdrawal and brain damage).



Hepato-biliary concerns



As Haloperidol is metabolised by the liver, caution is advised in patients with liver disease. Isolated cases of liver function abnormalities or hepatitis, most often cholestatic, have been reported.



Endocrine system concerns



Thyroxin may facilitate Haloperidol toxicity. Antipsychotic therapy in patients with hyperthyroidism should be used only with great caution and must always be accompanied by therapy to achieve a euthyroid state.



Hormonal effects of antipsychotic neuroleptic drugs include hyperprolactinaemia, which may cause galactorrhoea, gynaecomastia and oligo- or amenorrhoea. Very rare cases of hypoglycaemia and of Syndrome of Inappropriate ADH Secretion have been reported.



Venous thromboembolism



Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Haloperidol and preventive measures undertaken.



Additional considerations



In schizophrenia, the response to antipsychotic drug treatment may be delayed. Also, if drugs are withdrawn, recurrence of symptoms may not become apparent for several weeks or months.



Acute withdrawal symptoms including nausea, vomiting and insomnia have very rarely been described after abrupt cessation of high doses of anti-psychotic drugs. Relapse may also occur and gradual withdrawal is advisable.



Like all other antipsychotic agents, haloperidol should not be used alone where depression is predominant. It may be combined with antidepressants to treat those conditions in which depression and psychosis co-exist.



Caution is advised in patients with renal failure and phaeochromocytoma.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Concomitant use of haloperidol with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore concomitant use of these products is not recommended (see section 4.3-Contraindications).



Examples include certain antiarrhythmics, such as those of Class 1A (such as quinidine, disopyramide and procainamide) and class III (such as amiodarone, sotalol and dofetilide), certain antimicrobials (sparfloxacin, moxifloxacin, erythromycin IV), tricyclic antidepressants (such as amitriptyline), certain tetracyclic antidepressants (such as maprotiline), other neuroleptics (e.g. phenothiazines, pimozide and sertindole), certain antihistamines (such as terfenadine), cisapride, bretylium and certain anti-malarials such as quinine and mefloquine. This list is not comprehensive.



Concurrent use of drugs causing electrolyte imbalance may increase the risk of ventricular arrhythmias and is not recommended (see section 4.4-Special Warnings and Precautions for Use). Diuretics, in particular those causing hypokalaemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.



Haloperidol is metabolised by several routes, including glucuronidation and the cytochrome P450 enzyme system (particularly CYP 3A4 or CYP 2D6). Inhibition of these routes of metabolism by another drug or a decrease in CYP 2D6 enzyme activity may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation. In pharmacokinetic studies, mild to moderately increased haloperidol concentrations have been reported when haloperidol was given concomitantly with drugs characterised as substrates or inhibitors of CYP 3A4 or CYP 2D6 isozymes, such as, itraconazole, buspirone, venlafaxine, alprazolam, fluvoxamine, quinidine, fluoxetine, sertraline, chlorpromazine, and promethazine. A decrease in CYP2D6 enzyme activity may result in increased haloperidol concentrations. Increases in QTc and extrapyramidal symptoms have been observed when haloperidol was given with a combination of the metabolic inhibitors ketoconazole (400 mg/day) and paroxetine (20 mg/day). It may be necessary to reduce the haloperidol dosage.



Effect of Other Drugs on Haloperidol



When prolonged treatment with enzyme-inducing drugs such as carbamazepine, phenobarbital, rifampicin is added to Haloperidol therapy, this results in a significant reduction of haloperidol plasma levels. Therefore, during combination treatment, the Haloperidol dose should be adjusted, when necessary. After stopping such drugs, it may be necessary to reduce the dosage of Haloperidol.



Sodium valproate, a drug known to inhibit glucuronidation, does not affect haloperidol plasma concentrations.



Effect of Haloperidol on Other Drugs



In common with all neuroleptics, Haloperidol can increase the central nervous system depression produced by other CNS-depressant drugs, including alcohol, hypnotics, sedatives or strong analgesics. An enhanced CNS effect, when combined with methyldopa, has also been reported.



Haloperidol may antagonise the action of adrenaline and other sympathomimetic agents and reverse the blood-pressure-lowering effects of adrenergic-blocking agents such as guanethidine.



Haloperidol may impair the antiparkinson effects of levodopa.



Haloperidol is an inhibitor of CYP 2D6. Haloperidol inhibits the metabolism of tricyclic antidepressants, thereby increasing plasma levels of these drugs.



Other Forms of Interaction



In rare cases, an encephalopathy-like syndrome has been reported in combination with lithium and haloperidol. It remains controversial whether these cases represent a distinct clinical entity or whether they are in fact cases of NMS and/or lithium toxicity. Signs of encephalopathy-like syndrome include confusion, disorientation, headache, disturbances of balance and drowsiness. One report showing symptomless EEG abnormalities on the combination has suggested that EEG monitoring might be advisable. When lithium and haloperidol therapy are used concomitantly, haloperidol should be given in the lowest effective dose and lithium levels should be monitored and kept below 1 mmol/l. If symptoms of encephalopathy-like syndrome occur, therapy should be stopped immediately.



Antagonism of the effect of the anticoagulant phenindione has been reported.



The dosage of anticonvulsants may need to be increased to take account of the lowered seizure threshold.



4.6 Pregnancy And Lactation



The safety of haloperidol in pregnancy has not been established. There is some evidence of harmful effects in some but not all animal studies.



There have been a number of reports of birth defects following foetal exposure to haloperidol for which a causal role for haloperidol cannot be excluded. Reversible extrapyramidal symptoms have been observed in neonates exposed to haloperidol in utero during the last trimester of pregnancy. Haloperidol should be used during pregnancy only if the anticipated benefit outweighs the risk and the administered dose and duration of treatment should be as low and as short as possible.



Haloperidol is excreted in breast milk. There have been isolated cases of extrapyramidal symptoms in breast-fed children. If the use of Haloperidol is essential, the benefits of breast-feeding should be balanced the potential risks.



4.7 Effects On Ability To Drive And Use Machines



Haloperidol may cause some degree of sedation or impaired alertness, particularly at higher doses and at the start of treatment. Patients should be advised not to drive or operate machinery until their individual susceptibility is known.



4.8 Undesirable Effects



The data provided below covers all haloperidol formulations including the Haloperidol Decanoate formulations.



Very common (




























































































































System Organ Class




Adverse Drug Reactions



Frequency Category


    


Very Common



(




Common



(




Uncommon



(




Rare



(




Not Known


 


Blood and lymphatic System Disorders



 

 


Leukopenia



 


Agranulocytosis; Neutropenia; Pancytopenia; Thrombocytopenia




Immune System Disorders



 

 


Hypersensitivity



 


Anaphylactic reaction




Endocrine Disorders



 

 

 


Hyperprolactinaemia




Inappropriate antidiuretic hormone secretion




Metabolic and Nutritional Disorders



 

 

 

 


Hypoglycaemia




Psychiatric Disorders




Agitation; Insomnia




Depression; Psychotic disorder




Confusional state; Libido Decreased; Loss of libido; Restlessness



 

 


Nervous System Disorders




Extrapyramidal disorder; Hyperkinesia; Headache




Tardive dyskinesia; Oculogyric Crisis; Dystonia; Dyskinesia; Akathisia; Bradykinesia; Hypokinesia; Hypertonia; Somnolence; Masked Facies, Tremor; Dizziness




Convulsion; Parkinsonism; Akinesia; Cogwheel rigidity; Sedation; Muscle Contractions Involuntary




Motor dysfunction; Neuroleptic malignant syndrome; Nystagmus;



 


Eye Disorders



 


Visual disturbance;




Vision blurred



 

 


Cardiac Disorders



 

 


Tachycardia



 


Ventricular Fibrillation; Torsade de pointes; Ventricular Tachycardia; Extrasystoles




Vascular Disorders



 


Orthostatic Hypotension; Hypotension



 

 

 


Respiratory, thoracic and mediastinal Disorders



 

 


Dyspnoea




Bronchospasm




Laryngeal Oedema; Laryngospasm




Gastrointestinal Disorders



 


Constipation; Dry mouth; Salivary hypersecretion; Nausea; Vomiting



 

 

 


Hepatobiliary Disorders



 


Liver function test abnormal




Hepatitis; Jaundice



 


Acute Hepatic Failure; Cholestasis




Skin and subcutaneous tissue disorders



 


Rash




Photosensitivity Reaction; Urticaria; Pruritis; Hyperhidrosis



 


Leukocytoclastic Vasculitis; Dermatitis Exfoliative




Musculoskeletal and Connective Tissue Disorders



 

 


Torticollis; Muscle rigidity; Muscle Spasms; Musculoskeletal stiffness




Trismus; Muscle Twitching



 


Renal and Urinary Disorders



 


Urinary retention



 

 

 


Reproductive System and Breast Disorders



 


Erectile dysfunction




Amenorrhoea; Dysmenorrhoea; Galactorrhoea; Breast Discomfort; Breast Pain;




Menorrhagia; Menstrual Disorder; Sexual Dysfunction




Gynaecomastia, Priapism




General Disorders and Administration Site Conditions



 


Injection Site Reaction




Gait disturbance; Hyperthermia; Oedema



 


Sudden Death; Face Oedema; Hypothermia




Investigations



 


Weight increased; Weight decreased



 


Electrocardiogram QT prolonged



 


Additional Information



Cardiac effects such as QT-interval prolongation, torsade de pointes, ventricular arrhythmias, including ventricular fibrillation and ventricular tachycardia), and cardiac arrest have been reported. These effects may occur more frequently with high doses, and in predisposed patients.



Toxic epidermal necrolysis and Stevens-Johnson syndrome have been reported in patients taking haloperidol. The true incidence of these reports is not known.



Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs- Frequency unknown.



4.9 Overdose



Symptoms:



In general, the manifestations of haloperidol overdosage are an extension of its pharmacological actions, the most prominent of which would be severe extrapyramidal symptoms, hypotension and psychic indifference with a transition to sleep. The risk of ventricular arrhythmias possibly associated with QT-prolongation should be considered. The patient may appear comatose with respiratory depression and hypotension which could be severe enough to produce a shock-like state. Paradoxically hypertension rather than hypotension may occur. Convulsions may also occur.



Treatment:



There is no specific antidote to haloperidol. A patent airway should be established and maintained with mechanically assisted ventilation if necessary. In view of isolated reports of arrhythmia, ECG monitoring is strongly advised. Hypotension and circulatory collapse should be treated by plasma volume expansion and other appropriate measures. Adrenaline should not be used. The patient should be monitored carefully for 24 hours or longer, body temperature and adequate fluid intake should be maintained.



In cases of severe extrapyramidal symptoms, appropriate anti-Parkinson medication should be administered.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Haloperidol is a member of the butyrophenone class of neuroleptic drugs and has antipsychotic, anti-anxiety and anti-emetic effects. Although the precise central mechanism of action has not been elucidated, antagonism of dopamine-mediated synaptic neurotransmission appears to be an important action of haloperidol and may be the primary action through which the antipsychotic and extrapyramidal neurologic effects are mediated.



Within the autonomic nervous system, haloperidol displays less α-adrenergic antagonism than chlorpromazine and shows little anti-adrenergic activity in treated patients. The cholinergic blocking effects of antipsychotic drugs are relatively weak and anti-cholinergic effects are infrequent with haloperidol, relative to other neuroleptic agents.



Orthostatic hypotension, seen with chlorpromazine and resulting from a combination of central actions and peripheral α-adrenergic blockade, occurs much less frequently during therapy with haloperidol.



5.2 Pharmacokinetic Properties



Haloperidol is readily absorbed from the gastro-intestinal tract. It is metabolised in the liver and is excreted in the urine and faeces. There is wide inter-subject variation in plasma concentrations of haloperidol. The drug is very extensively bound to plasma proteins. It is widely distributed in the body and it crosses the blood-brain barrier. The plasma half-life of haloperidol is reported to range from about 13 to nearly 40 hours.



5.3 Preclinical Safety Data



No further relevant information other than that which is included in other sections of the Summary of Product Characteristics.



6. Pharmaceutical Particulars



6.1 List Of Excipients










Lactose B.P.




Polyvinylpyrrolidone B P / Povidone




Starch B.P.




Magnesium Stearate B.P.




Stearic Acid B.P.C.




Water



6.2 Incompatibilities



Nil.



6.3 Shelf Life



3 years (36 months).



6.4 Special Precautions For Storage



Store below 20°C.



Protect from light.



6.5 Nature And Contents Of Container



Polypropylene securitainers with tamper evident polypropylene caps.



Pack size: 25, 50, 100, 250, 500 and 1,000 tablets.



6.6 Special Precautions For Disposal And Other Handling



Use as directed by the physician.



Keep out of reach of children.



Administrative Data


7. Marketing Authorisation Holder



Goldshield Pharmaceuticals Ltd



NLA Tower



12-16 Addiscombe Road



Croydon



Surrey



CR0 0XT



United Kingdom



8. Marketing Authorisation Number(S)



PL 12762/0112



9. Date Of First Authorisation/Renewal Of The Authorisation



25th July 2001



10. Date Of Revision Of The Text



10/09/2010